Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 11/20 | 0.49 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.45 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 3/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1896568 | 0.86 | PTK2 (0.53) | PTK2MAPTBRAFFYN | |
| SCHEMBL1903800 | 0.83 | PTK2 (0.52) | PTK2MEN1KMT2ABRAFFYN | |
| SCHEMBL1899063 | 0.83 | PTK2 (0.50) | PTK2MEN1MAPTKMT2ABRAF | |
| SCHEMBL1900945 | 0.82 | PTK2 (0.50) | PTK2MEN1KMT2ABRAFFYN | |
| SCHEMBL1900811 | 0.82 | PTK2 (0.50) | PTK2MAPTBRAFFYNPOLB | |
| SCHEMBL1900601 | 0.82 | PTK2 (0.47) | PTK2MEN1MAPTKMT2ABRAF | |
| SCHEMBL1899828 | 0.82 | PTK2 (0.49) | PTK2MEN1KMT2ABRAF | |
| SCHEMBL1900170 | 0.81 | PTK2 (0.50) | PTK2MAPTBRAF | |
| SCHEMBL1896948 | 0.80 | PTK2 (0.71) | PTK2FYN | |
| SCHEMBL14553115 | 0.80 | PTK2 (0.48) | PTK2MAPTBRAFFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422307-B2 | 2,4,7-substituted thieno[3,2-d]pyrimidine compounds as protein kinase inhibitors | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2016-08-23 | — | — | US | claimed |
| US-20130012703-A1 | 2,4,7-SUBSTITUTED THIENO[3,2-D]PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2013-01-10 | — | — | US | claimed |
| WO-2011062372-A2 | 2, 4, 7 -SUBSTITUTED THIENO [3, 2 -D] PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2011-05-26 | — | — | WO | claimed |
| US-9422307-B2 | 2,4,7-substituted thieno[3,2-d]pyrimidine compounds as protein kinase inhibitors | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2016-08-23 | — | — | US | disclosed |
| US-9422307-B2 | 2,4,7-substituted thieno[3,2-d]pyrimidine compounds as protein kinase inhibitors | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2016-08-23 | — | — | US | disclosed |
| US-9422307-B2 | 2,4,7-substituted thieno[3,2-d]pyrimidine compounds as protein kinase inhibitors | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2016-08-23 | — | — | US | disclosed |
| US-20130012703-A1 | 2,4,7-SUBSTITUTED THIENO[3,2-D]PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2013-01-10 | — | — | US | disclosed |
| US-20130012703-A1 | 2,4,7-SUBSTITUTED THIENO[3,2-D]PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2013-01-10 | — | — | US | disclosed |
| US-20130012703-A1 | 2,4,7-SUBSTITUTED THIENO[3,2-D]PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2013-01-10 | — | — | US | disclosed |
| WO-2011062372-A2 | 2, 4, 7 -SUBSTITUTED THIENO [3, 2 -D] PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011062372-A2 | 2, 4, 7 -SUBSTITUTED THIENO [3, 2 -D] PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012703-A1 | 2,4,7-SUBSTITUTED THIENO[3,2-D]PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | CDK2, TK1, MAP4K2 | PTK2 241/4885IMPDH2 630/4885TMIGD3 1804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.